← Issue №19/ week of Nov 8, 2026/ the whole section, in full

Motility, in full.

All 7 Motility papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 7, in full

most clinically useful first
Motility prospective cohort · n=401 · Nov 5, 2026 · Clin Gastro Hep · IF 16.2

Latent Class Analysis May Predict Patients with Irritable Bowel Syndrome Who Respond to Amitriptyline: Post Hoc Analyses from ATLANTIS.

New evidenceIBSbiomarkerartificial intelligence
Clinical takeawayNo change to who is offered low-dose amitriptyline for IBS: the clusters are exploratory. Expect more discontinuation and side effects in patients with severe combined gut and psychological symptoms.
What it foundAmitriptyline reduced IBS-SSS by 103.44 vs placebo's 61.89 in patients with predominant psychological symptoms and milder gastrointestinal symptoms (cluster 3), p=0.045.
ContextLow-dose amitriptyline was superior to placebo overall in ATLANTIS; this analysis of 401 participants asked whether symptom clusters modify that.
Refinessuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Diagnosis: use a positive diagnostic strategy based on Rome IV criteria rather than a strategy of exclusion (strong for cost-effectiveness, high quality; consensus for time-to-therapy), and categorize by IBS subtype (consensus). In patients with IBS and diarrhea symptoms: check celiac serology (strong, moderate) and, in those WITHOUT alarm features, fecal calprotectin (or fecal lactoferrin) plus CRP to rule out IBD (strong; moderate quality for CRP/calprotectin, very low for lactoferrin). Recommend AGAINST routine stool testing for enteric pathogens (conditional, low) and AGAINST routine colonoscopy in patients younger than 45 without warning signs (conditional, low). Anorectal physiology testing only when symptoms suggest a pelvic floor disorder and/or for refractory constipation not responding to standard medical therapy (consensus). Treatment, all subtypes: soluble, not insoluble, fiber (strong, moderate); a LIMITED trial of a low-FODMAP diet (conditional, very low); gut-directed psychotherapies for global symptoms (conditional, very low); TCAs for global symptoms (strong, moderate); peppermint suggested (conditional, low); antispasmodics for abdominal pain (conditional, low); AGAINST probiotics (conditional, very low), AGAINST fecal transplant (strong, very low). IBS-C: chloride channel activators (strong, moderate) and guanylate cyclase activators (strong, high); AGAINST PEG products for global IBS-C symptoms (conditional, low); tegaserod reserved for women younger than 65 with ≤1 cardiovascular risk factor who have not adequately responded to secretagogues (strong/conditional, low). IBS-D: rifaximin (strong, moderate); alosetron only for women with severe IBS-D who have failed conventional therapy (conditional, low); mixed opioid agonists/antagonists, i.e. eluxadoline (conditional, moderate); AGAINST bile acid sequestrants (conditional, very low).

American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021 · reviewed 2026-07-21 ↗
Black CJ … ATLANTIS trialists · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Motility retrospective · n=81 · Nov 1, 2026 · Neurogastro Motil · IF 3.5

Similar Tolerance of Glucagon-Like PEPTIDE-1 Agonist Therapy in Patients With Delayed and Normal Gastric Emptying.

New evidencegastroparesis
Clinical takeawayPrior delayed emptying on scintigraphy need not by itself rule out a GLP-1RA, but this retrospective series had only 14 such patients and cannot establish safety.
What it foundGI symptoms developed in 36% with delayed vs 52% with normal emptying (p=0.38); among patients who stopped the drug, GI symptoms were the reason in 3 of 8 vs 11 of 37 (p=0.70), and treatment durations were similar (318 vs 193 days, p=0.31). Injectable semaglutide was the most commonly prescribed GLP-1RA.
ContextThe authors conclude the data do not support strictly avoiding GLP-1RAs in gastroparesis; overall, 56% stopped the drug, 31% of them for GI symptoms.
Emergingsuggested applicable standard· American Gastroenterological Association (AGA), 'AGA Clinical Practice Guideline on Management of Gastroparesis', Staller K, Parkman HP, Greer KB, Leiman DA, Zhou MJ, Singh S, Camilleri M, Altayar O; AGA Clinical Guidelines Committee. Gastroenterology. 2025 Oct;169(5):828-861. doi:10.1053/j.gastro.2025.08.004. PMID 40976635 (published online 19 Sept 2025)

Decision at stakewhether to prescribe GLP-1 receptor agonists in patients with gastroparesis

… Testing should be done without confounders: hyperglycaemia and drugs that alter emptying (opioids, GLP-1 receptor agonists, prokinetics). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Scope: individuals with suspected or confirmed idiopathic or diabetic gastroparesis, including medically refractory disease. All 12 recommendations are CONDITIONAL ('suggests'), at low or very low certainty of evidence; none are strong. DIAGNOSIS (Rec 1): AGA suggests against a 2-hour (or shorter) gastric emptying study and in favour of a 4-hour study [conditional, low certainty], because patients with normal emptying at 2 hours may be reclassified as delayed at 4 hours. The 4-hour value must be measured directly at 4 hours, not mathematically derived from earlier time points. Testing should be done without confounders: hyperglycaemia and drugs that alter emptying (opioids, GLP-1 receptor agonists, prokinetics). Two meals have well-established normal values: the low-fat Tougas/EggBeaters meal (liquid egg white, bread, jam, water; 250 kcal, 2% fat) and the Mayo Clinic meal (two whole eggs, bread, skim milk; 320 kcal, 30% fat), the latter more thoroughly validated. PHARMACOTHERAPY: AGA suggests USING metoclopramide (Rec 2) and USING erythromycin (Rec 3), each conditional/very low certainty. Metoclopramide, oral tablet/liquid or intranasal, start 5 mg before meals, may increase up to 10 mg before meals; discuss potential side effects before starting (tardive dyskinesia risk noted, absolute risk low; higher risk of adverse events leading to discontinuation in older patients and those on psychotropics); assess efficacy and side effects at 4-8 weeks to decide on continuation, then monitor for the duration of therapy. Patients placing higher value on adverse-event risk and lower value on symptom improvement may reasonably decline it. Erythromycin, low dose (e.g. 100-150 mg by mouth, 30 min before meals) to reduce side effects seen at 250-500 mg; ethylsuccinate oral suspension allows smaller doses since tablets come only in high strengths; prokinetic via motilin agonism with no direct antiemetic effect; tachyphylaxis with prolonged continuous use is managed by drug holidays (e.g. 3 weeks on, 1 week off); cautions include QT prolongation, CYP3A interactions and antibiotic resistance. AGA suggests AGAINST, as first-line therapy, with shared-decision carve-outs, domperidone (Rec 4), prucalopride (Rec 5), aprepitant (Rec 6), nortriptyline (Rec 7.1) and buspirone (Rec 7.2) [conditional; low to very low certainty], and against cannabidiol EXCEPT in the context of a clinical trial (Rec 8, conditional/low certainty). Each carries an explicit shared-decision-making carve-out naming who may still reasonably use it: domperidone for patients who had neurological side effects on metoclopramide or who have movement disorders such as Parkinson's disease (US use requires an FDA expanded-access IND, and the sole US supplier is exiting; obtain baseline potassium, magnesium and ECG QTc, monitor on therapy, reassess at 4-8 weeks); prucalopride particularly in idiopathic gastroparesis (patients with diabetic or connective-tissue-disease-related gastroparesis are less likely to respond) and in those with coexisting chronic idiopathic constipation, noting the depression/suicidality monitoring warning; aprepitant for nausea and vomiting not helped by 5-HT3 antagonists such as ondansetron, recognising it has no effect on gastric motor function; nortriptyline for coexisting IBS or significant abdominal pain, started at low dose and titrated slowly, framed to patients as a peripheral neuromodulator; buspirone for predominant early satiety and bloating. For cannabidiol the panel notes the single positive trial used pharmaceutical-grade Epidiolex, which is not available for clinical use in gastroparesis, that commercial formulations are unregulated and variable in potency, and that THC-containing products raise cannabinoid hyperemesis concern. PROCEDURES (medically refractory disease): AGA suggests against G-POEM EXCEPT for selected patients with medically refractory disease (Rec 9, conditional/low certainty), candidates should have gastroparesis confirmed on an appropriately performed 4-hour gastric emptying study, generally with at least moderate delay (20% retention at 4 hours with the EggBeaters meal), at least six months of moderate cardinal symptoms (nausea, vomiting and/or postprandial fullness), and a prior trial of other treatments including a prokinetic such as metoclopramide plus an antiemetic. AGA suggests against pyloric botulinum toxin injection (Rec 11, conditional/very low certainty), noting that retreatment as often as every 3 months limits cost-effectiveness and that repeat treatment may cause pyloric scarring complicating later G-POEM; patients placing higher value on endoscopic intervention and lower value on chronic medical therapy may reasonably attempt it. AGA suggests against the ROUTINE INITIAL use of gastric electrical stimulation (Rec 12, conditional/very low certainty), reserving it, as with G-POEM, for select patients whose symptoms are refractory to medical therapy; patients placing higher value on potential nausea/vomiting improvement and lower value on the increase in serious adverse events may reasonably select GES, and should be told it aims to improve nausea and vomiting, not abdominal pain. For surgical pyloric interventions (pyloromyotomy or pyloroplasty) AGA makes NO recommendation and designates a knowledge gap, advising use only in the context of clinical trials (Rec 10). NON-GRADED adjuncts appear only as implementation considerations, not recommendations: panel content experts use small-particle, low-fat, low-residue diets before or alongside pharmacotherapy, and as-needed antiemetics (5-HT3 antagonists e.g. ondansetron, H1 antagonists e.g. promethazine, D2 antagonists e.g. prochlorperazine); efficacy of pharmacological interventions is assessed at 4-8 weeks. The guideline does NOT address exclusion of mechanical obstruction, enteral/J-tube nutrition, glycaemic targets, or perioperative GLP-1 RA management, those remain with the supporting documents.

American Gastroenterological Association (AGA), 'AGA Clinical Practice Guideline on Management of Gastroparesis', Staller K, Parkman HP, Greer KB, Leiman DA, Zhou MJ, Singh S, Camilleri M, Altayar O; AGA Clinical Guidelines Committee. Gastroenterology. 2025 Oct;169(5):828-861. doi:10.1053/j.gastro.2025.08.004. PMID 40976635 (published online 19 Sept 2025) · reviewed 2026-07-19 ↗
Rolak SC … Hasler WL · Neurogastroenterology and Motility · IF 3.5 · PubMed ↗Permalink
Motility guideline · Nov 1, 2026 · Neurogastro Motil · IF 3.5

Diagnosis and Management of Achalasia in Children, BSPGHAN and BAPS Consensus Statement.

Guideline / reviewpediatricguidelineesophageal motilityachalasia
Clinical takeawayUse high-resolution manometry as the primary diagnostic investigation for suspected pediatric achalasia, supplemented by timed barium oesophagogram and endoscopy. Consider peroral endoscopic myotomy or laparoscopic Heller's myotomy as first-line definitive treatments, guided by achalasia subtype, center expertise, and family preference. Ensure structured transition to adult care and implement long-term surveillance.
What it foundHigh-resolution manometry is recommended as the primary diagnostic tool for pediatric achalasia, with timed barium oesophagogram and endoscopy as complementary modalities. Peroral endoscopic myotomy and laparoscopic Heller's myotomy are recommended as first-line definitive treatments.
ContextThis consensus statement fills a gap by providing the first pediatric-specific guidelines for achalasia, where previously only adult guidelines existed.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Mutalib M … Papadopoulos M · Neurogastroenterology and Motility · IF 3.5 · PubMed ↗Permalink
Motility retrospective · n=133 · Nov 1, 2026 · Neurogastro Motil · IF 3.5

Anorectal Manometry and Balloon Expulsion Testing in Chronic Constipation: Concordance, Manometric Predictors of Dyssynergic Defecation, and Implications for Biofeedback Referral.

New evidencechronic constipationanorectal manometry
Clinical takeawayConsider using both anorectal manometry (ARM) and balloon expulsion test (BET) in chronic constipation patients suspected of dyssynergic defecation, as relying on either test alone may misclassify patients. Biofeedback improved symptoms in 19 of 21 patients with positive tests.
What it foundARM-BET agreement was slight (56%, kappa 0.17), with 30% abnormal on both tests, 44% on one test, and 26% normal on both.
ContextConfirms prior evidence that ARM and BET are complementary but not interchangeable, and refines understanding by showing continuous physiologic measures (rectoanal gradient) predict BET better than the Rao classification. Lower resting anal pressure was independently associated with the dyssynergic pattern.
Measured against the standard of care· AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993)

… Most patients should have anorectal testing and, when indicated, pelvic floor biofeedback before being labeled refractory. … For obstructed defecation and posterior compartment or rectal prolapse, a 2026 consensus of the ASCRS Pelvic Floor Consortium with ICS, IUGA, AUGS and APTA (15 statements, >70% consensus, expert-consensus evidence) advises prompt referral to pelvic floor physical therapy for patients without contraindications. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

First-line drug treatment for adults with chronic idiopathic constipation has not changed. It still follows the AGA-ACG 2023 GRADE guideline. STRONG recommendation (moderate certainty) for polyethylene glycol. STRONG recommendation (moderate certainty) for bisacodyl or sodium picosulfate, limited to short-term or rescue use. CONDITIONAL suggestion for fiber (low certainty), magnesium oxide (very low) and senna (low). For patients who do not respond to, fail, or cannot tolerate over-the-counter agents: STRONG recommendation (moderate certainty) for linaclotide, plecanatide and prucalopride, and CONDITIONAL suggestion for lubiprostone (low) and lactulose (very low). The guideline gives no doses, no required order and no fixed trial length; it uses shared decision making and leaves anorectal evacuation disorders to the ACG 2021 benign anorectal guideline. Added on top of this is the AGA 2026 Clinical Practice Update on refractory constipation (Staller, Neshatian, Lembo, Bharucha; expert-opinion Best Practice Advice, 14 key clinical issues, no formal evidence grading). Before calling constipation refractory, clinicians should systematically (1) exclude correctable secondary causes: medications, neurologic disorders, and defecatory disorders; (2) confirm slow colonic transit objectively, ideally both off therapy and on maximal therapy; and (3) make sure the patient has had adequate trials of over-the-counter and FDA-approved drugs and nonpharmacologic therapy, including combinations. Most patients should have anorectal testing and, when indicated, pelvic floor biofeedback before being labeled refractory. Colectomy can be considered only after all of these fail. Before surgery: confirm slow transit, exclude a concurrent defecatory disorder, evaluate for severe symptomatic delayed gastric emptying or small-bowel dysmotility, and do a psychological evaluation. Relative contraindications are clinically significant upper-gut dysmotility, severe untreated psychiatric disease, and bloating or abdominal pain as the main complaint. A temporary diverting loop ileostomy may predict response in uncertain cases. Colectomy with ileorectal anastomosis should be offered only to patients without an ongoing defecatory disorder. For obstructed defecation and posterior compartment or rectal prolapse, a 2026 consensus of the ASCRS Pelvic Floor Consortium with ICS, IUGA, AUGS and APTA (15 statements, >70% consensus, expert-consensus evidence) advises prompt referral to pelvic floor physical therapy for patients without contraindications. It also advises therapy individualized to the diagnostic evaluation and the patient's goals, deliberate timing of therapy relative to surgery, and trauma-informed care.

AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993) · reviewed 2026-10-25 ↗
Wilson O … Parkman HP · Neurogastroenterology and Motility · IF 3.5 · PubMed ↗Permalink
Motility guideline · Nov 1, 2026 · UEG Journal · IF 5.6

European Guidelines on Multidisciplinary Management of Obstructed Defecation Syndrome-ESCP, UEG, ESGAR, EAGEN, ESGENA, ESNM and ESPCG.

Guideline / reviewguidelinefunctional dyspepsiachronic constipationfecal incontinence
Clinical takeawayManage obstructed defecation conservatively first; offer biofeedback before surgery in patients with dyssynergic defecation who fail dietary and laxative treatment, and reserve surgery for selected patients with persistent symptoms after multidisciplinary pelvic floor evaluation.
What it foundThe guideline includes 28 statements (1 moderate, 2 low, 3 very low grade evidence, 22 expert opinion) on ODS diagnosis and management, emphasizing multidisciplinary care.
ContextSeven European societies; 22 of 28 statements rest on expert opinion, so individualized multidisciplinary decision-making remains central.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Gallo G … Picciariello A · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
Motility prospective cohort · n=1,632 · Nov 1, 2026 · Neurogastro Motil · IF 3.5

Prevalence and Burden of Disorders of Gut-Brain Interaction in Nigeria: Results From the Rome Foundation Global Epidemiology Study.

Epidemiologyepidemiologybasic sciencehealth services
Clinical takeawayConsider DGBI as a common contributor to gastrointestinal symptoms and reduced quality of life in Nigerian adults, particularly women and those in northern regions.
What it foundThe prevalence of any disorder of gut-brain interaction (DGBI) in Nigeria was 23.5%, with bowel disorders being the most common (17.6%). Females had a higher prevalence (26.1%) than males (21.0%), and northern regions reported higher prevalence than southern regions.
ContextThis study confirms the high prevalence and impact of DGBI in Nigerian adults, aligning with global findings and highlighting regional and gender disparities.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Aliyu AI … Simrén M · Neurogastroenterology and Motility · IF 3.5 · PubMed ↗Permalink
Motility prospective cohort · n=618 · Nov 1, 2026 · UEG Journal · IF 5.6

Intestinal Permeability in Irritable Bowel Syndrome With and Without Comorbid Conditions: Results From the European DISCOvERIE Cohort.

Basic scienceIBSbiomarkerepidemiologybasic science
Clinical takeawayNo clinical action yet: this study identifies a mechanistic difference in intestinal permeability in IBS patients but does not support a specific diagnostic or therapeutic intervention.
What it foundIBS patients had a higher lactulose/mannitol (L/M) ratio (driven by lower mannitol excretion) compared to disease controls, with no difference between IBS patients with and without comorbidities.
ContextConfirms prior evidence implicating intestinal-barrier dysfunction in IBS pathophysiology but clarifies that comorbidities do not further exacerbate permeability changes.
Emergingsuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Diagnosis: use a positive diagnostic strategy based on Rome IV criteria rather than a strategy of exclusion (strong for cost-effectiveness, high quality; consensus for time-to-therapy), and categorize by IBS subtype (consensus). In patients with IBS and diarrhea symptoms: check celiac serology (strong, moderate) and, in those WITHOUT alarm features, fecal calprotectin (or fecal lactoferrin) plus CRP to rule out IBD (strong; moderate quality for CRP/calprotectin, very low for lactoferrin). Recommend AGAINST routine stool testing for enteric pathogens (conditional, low) and AGAINST routine colonoscopy in patients younger than 45 without warning signs (conditional, low). Anorectal physiology testing only when symptoms suggest a pelvic floor disorder and/or for refractory constipation not responding to standard medical therapy (consensus). Treatment, all subtypes: soluble, not insoluble, fiber (strong, moderate); a LIMITED trial of a low-FODMAP diet (conditional, very low); gut-directed psychotherapies for global symptoms (conditional, very low); TCAs for global symptoms (strong, moderate); peppermint suggested (conditional, low); antispasmodics for abdominal pain (conditional, low); AGAINST probiotics (conditional, very low), AGAINST fecal transplant (strong, very low). IBS-C: chloride channel activators (strong, moderate) and guanylate cyclase activators (strong, high); AGAINST PEG products for global IBS-C symptoms (conditional, low); tegaserod reserved for women younger than 65 with ≤1 cardiovascular risk factor who have not adequately responded to secretagogues (strong/conditional, low). IBS-D: rifaximin (strong, moderate); alosetron only for women with severe IBS-D who have failed conventional therapy (conditional, low); mixed opioid agonists/antagonists, i.e. eluxadoline (conditional, moderate); AGAINST bile acid sequestrants (conditional, very low).

American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021 · reviewed 2026-07-21 ↗
Rustichelli A … Farré R · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
← Back to issue №19 Every section of this issue is one click away, at the top of this page. Follow Motility by RSS